Europeans warm to pharma info

Share this article:

A Manhattan Research survey found that “nearly two in five online Europeans would like to be able to learn more about prescription drugs directly from a pharmaceutical company,” with Italians most keen on interacting with pharmas and Germans least interested.

That data point may gladden advocates of liberalizing the strict restrictions on drug company contacts with consumers that typify marketing regulations in the EU and EU member countries. The European Commission has flirted in recent years with loosening restrictions, but ratcheted back on that with a proposed policy update released in this past fall.

Europeans were less interested in getting online contests and games from pharmas than they were practical resources like disease and treatment information or condition management tools, and they were largely disinterested in visiting pharma Facebook or Twitter pages.

The findings came from Manhattan Research's Cybercitizen Health Europe 2011 survey of 3,020 adults in the UK, France, Germany, Italy and Spain.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.